James Greger
Impact in
Papers in
- Co-authors
- Anna Marie Skalka (9 shared papers)Richard A. Katz (9 shared papers)Tona M. Gilmer (3 shared papers)Boris J. Cheskis (2 shared papers)Li Liu (2 shared papers)Anne‐Marie Martin (2 shared papers)Leonard P. Freedman (1 shared paper)Sunil Nagpal (1 shared paper)
- Journals
- Journal of Virology (6 papers)Molecular Cancer Therapeutics (2 papers)Cancer Chemotherapy and Pharmacology (1 paper)Clinical Genitourinary Cancer (1 paper)Journal of Cellular Biochemistry (1 paper)
- Partner nations
- United StatesRussiaSpain
In The Last Decade
James Greger
22 papers receiving 1.9k citations
James Greger's Hit Papers
Peers
Comparison fields: 5 of 64
- Virology 135
- Oncology 242
- Pulmonary and Respiratory Medicine 328
- Molecular Biology 361
- Genetics 135
Countries citing papers authored by James Greger
This map shows the geographic impact of James Greger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Greger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Greger more than expected).
Fields of papers citing papers by James Greger
This network shows the impact of papers produced by James Greger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Greger. The network helps show where James Greger may publish in the future.
Co-authors
The 25 scholars most cited alongside James Greger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 412 | |
| 2 | Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study Hit paper breakdown → | 2023 | 301 |
| 3 | 2012 | 297 | |
| 4 | 2007 | 182 | |
| 5 | 2003 | 93 | |
| 6 | 2004 | 84 | |
| 7 | 2011 | 68 | |
| 8 | 2002 | 63 | |
| 9 | 2005 | 53 | |
| 10 | 2003 | 51 | |
| 11 | 2023 | 51 | |
| 12 | 2004 | 49 | |
| 13 | 2013 | 49 | |
| 14 | 2005 | 40 | |
| 15 | 2007 | 32 | |
| 16 | 2005 | 27 | |
| 17 | 2004 | 23 | |
| 18 | 2022 | 18 | |
| 19 | 2024 | 13 | |
| 20 | 2004 | 6 |
About James Greger
James Greger is a scholar working on Oncology, Genetics, Virology, Pulmonary and Respiratory Medicine and Infectious Diseases, having authored 22 papers that have together received 1.9k indexed citations. Recurring topics across this work include Virus-based gene therapy research (3 papers), HER2/EGFR in Cancer Research (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), Estrogen and related hormone effects (2 papers), Prostate Cancer Treatment and Research (1 paper), Lung Cancer Treatments and Mutations (1 paper), HIV Research and Treatment (1 paper) and Monoclonal and Polyclonal Antibodies Research (1 paper). The work is most often cited by research in Virology (135 citations), Oncology (242 citations), Pulmonary and Respiratory Medicine (328 citations), Molecular Biology (361 citations) and Genetics (135 citations). James Greger has collaborated with scholars based in United States, Russia and Spain. Frequent co-authors include Anna Marie Skalka, Richard A. Katz, Tona M. Gilmer, Boris J. Cheskis, Li Liu, Anne‐Marie Martin, Leonard P. Freedman, Sunil Nagpal, Ganesh M. Sathe and Wendy S. Halsey. Their work appears in journals such as Journal of Virology, Molecular Cancer Therapeutics, Cancer Chemotherapy and Pharmacology, Clinical Genitourinary Cancer and Journal of Cellular Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.